Company profile
Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IKT-001PRO | phase2 | — | 2 | completed, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05623774 | phase1 | completed | 2022-12-16 | 2024-06-30 | Inhibikase Therapeutics | A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg |
| NCT06643143 | phase2 | withdrawn | 2025-06-30 | 2027-06-30 | Inhibikase Therapeutics | A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) |
| NCT07365332 | phase3 | recruiting | 2026-04-23 | 2029-06-01 | Inhibikase Therapeutics | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
| NCT07632898 | phase3 | not_yet_recruiting | 2026-10-23 | 2030-06-30 | Inhibikase Therapeutics | Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
FDA applications (0)
No records yet.